Skip to content

Clinical trials

Observational Pulmonary Arterial Hypertension trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Arterial Hypertension Phase: Observational Clear all

183 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20052
20062
20074
20083
20095
201010
201110
20126
201311
20149
201512
20167
201712
20187
20198
20208
202116
20228
20239
20249
202513
202611

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed86
Unknown status32
Recruiting29
Not yet recruiting12
Terminated10
Active, not recruiting6
Withdrawn5
Enrolling by invitation3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Bayer12
Actelion10
United Therapeutics6
Assistance Publique - Hôpitaux de Paris5
Mayo Clinic5
Central Hospital, Nancy, France4
Chinese Pulmonary Vascular Disease Research Group4
University of Giessen4
University of Sao Paulo General Hospital4
Northwell Health3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Arterial Hypertension183
Hypertension, Pulmonary57
Familial Primary Pulmonary Hypertension9
Heart Failure8
Scleroderma, Systemic8
Lung Diseases, Interstitial6
Heart Defects, Congenital5
Hypertension5
Lung Diseases4
Pulmonary Disease, Chronic Obstructive4

Trials

Showing 26 to 50 of 183. Each trial links to its page on Pharma Observatory.

83 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.